VETOQUINOL
22.11.2021 10:34:06 CET | Business Wire | Press release
Vetoquinol (Paris: VETO) is delighted to announce that, following positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), the European Commission has granted marketing authorisation for Felpreva® (tigolaner/emodepside/praziquantel) for spot-on prevention and treatment of mixed parasitic infestations/infections in cats.1
Felpreva® is the first spot-on parasiticide for cats that covers tapeworms in addition to other endoparasites including gastrointestinal roundworms and lungworms, and ectoparasites (fleas, ticks and mites) for up to three months with a single dose. It is licensed for treatment of cats with, or at risk from, mixed parasitic infestations/infections, including:
- Endoparasites:
- Gastrointestinal roundworms: infection with Toxocara cati, Toxascaris leonina
and Ancylostoma tubaeforme
- Lungworms: infection with Aelurostrongylus abstrusus
and Troglostrongylus brevior
- Tapeworms: infection with Dipylidium caninum
and Taenia taeniaeformis
- Ectoparasites:
- Flea (Ctenocephalides felis
), tick (Ixodes ricinus, Ixodes holocyclus
) and mite (Otodectes cynotis
) infestations, as well as mild to moderate cases of notoedric mange (caused by Notoedres cati
). It can also form part of a treatment strategy for flea allergic dermatitis (FAD).
Matthieu Frechin, Vetoquinol CEO, commented: “Marketing authorisation is a pivotal achievement for both Vetoquinol and Felpreva® . It is a breakthrough treatment with convenience and simplicity of use combined with long-lasting efficacy. We believe that Felpreva® will be a real game changer for this area of veterinary medicine, demonstrating our commitment to the parasiticide market.”
Felpreva® is part of the endectocide class of veterinary parasiticides that covers both internal (endo) and external (ecto) parasites. It is a combination of active substances emodepside and praziquantel, with tigolaner, a novel active ingredient.1
It is estimated that parasiticides make up the largest segment in the companion animal veterinary pharmaceutical market worldwide. Moreover, the fast-growing endectocide category is estimated to make up approximately one quarter of the total companion animal parasiticide market.2
Fifty percent of pet owners in Europe report currently treating their pets with an endectocide product.3 However, research suggests owners are treating cats less frequently than recommended by the European Scientific Counsel Companion Animal Parasites (ESCCAP), which recommends no less than four times per year for deworming in certain risk groups of cats.4.5
Juliana Carrer, International Range Manager at Vetoquinol, said: “With veterinary staff busier than ever, and increasing numbers of new cat owners across Europe, we understand the need to reduce prescribing complexity and increase vets’ confidence in owner compliance. As a qualified veterinarian myself I warmly welcome the approval of Felpreva® .”
It is anticipated that Felpreva® will be made available to veterinarians across Europe in early 2022.
ENDS
References
- European Commission Union Register of Veterinary Medicinal Products – Felpreva. 2021. Available from: https://ec.europa.eu/health/documents/community-register/html/v277.htm [Accessed 16 November 2021].
- Vetoquinol estimates, based on Market Intelligence Data.
- Survey of Pet Owners in EU6 countries and the UK, conducted by Metyis February 2021.
- McNamara, J., Drake, J., Wiseman, S. and Wright, I., 2018. Survey of European pet owners quantifying endoparasitic infection risk and implications for deworming recommendations. Parasites & Vectors, 11(1).
- ESCCAP Guideline 1: Worm Control in Dogs and Cats. 6th ed. Available at: https://www.esccap.org/uploads/docs/oc1bt50t_0778_ESCCAP_GL1_v15_1p.pdf [Accessed 16 November 2021].
ABOUT VETOQUINOL
Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets.
As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.
Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group’s hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vetoquinol employed 2,540 people as of September 30th, 2021.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).
The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.
For further information, go to: www.vetoquinol.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006075/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IAMPHENOM Europe 2026 Registration Opens: HR’s Leading Conference for Agentic AI Learning Returns20.5.2026 13:00:00 CEST | Press release
Europe’s CHROs, CIOs and HRIT Leaders Head to Paris for Learning How AI Redesigns Work Operations Across Hiring, Development and Retention Phenom, the leader in applied AI with an infrastructure built specifically to redesign work operations, today announced registration is open for IAMPHENOM Europe 2026, taking place 4-5 November in Paris, France. The only applied AI event dedicated to human resources on the continent, IAMPHENOM Europe gives HR and HRIT leaders the agentic AI strategies, instruction and proof points they need to build their AI-augmented workforce to address their biggest hiring, development and retention challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520683492/en/ Phenom today announced registration is open for IAMPHENOM Europe 2026. The only applied AI event dedicated to human resources on the continent is taking place 4-5 November in Paris, France. European organisations face pressure from
BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard20.5.2026 12:00:00 CEST | Press release
Campaign connects the preparation, precision, and grit that define great goalkeeping to the persistent scientific, clinical, and community efforts that drive progress in cancer careFeatures international goalkeepers, uniting soccer’s global reach with BeOne’s commitment to patients everywhere BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today launched One Save Changes Everything, a campaign that uses soccer as a lens to recognize the scientific, clinical, and human moments that matter in cancer care. The campaign launches with goalkeeping legends, including former U.S. Men’s National Team goalkeeper Tim Howard. The initiative is backed by a $300,000 community commitment for the installation of soccer mini-pitches near cancer treatment centers with the U.S. Soccer Foundation, and BeOne colleague‑driven charitable support across the world. This press release features multimedia. View the full release here: https://www.businesswire.com
Chiesi Group Announces New Chair and Vice Chair20.5.2026 11:00:00 CEST | Press release
Highlights:Planned transition in the Chair and Vice Chair roles reflects the Chiesi family’s long-term commitment to continuity, shared value and responsible governance across generationsMaria Paola Chiesi is appointed Chair, the first woman in this role; aims to reinforce sustainability as an integral and enduring pillar of the Group’s strategy Chiesi today announced a planned leadership change in its Board of Directors: Maria Paola Chiesi has been appointed Chair of the Board, succeeding Alessandro Chiesi, who is completing his tenure after nearly three years in the role, and will now continue to serve as Vice Chair. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520447292/en/ Maria Paola Chiesi is appointed Chair of Chiesi Board of Directors, the first woman in this role; aims to reinforce sustainability as an integral and enduring pillar of the Group’s strategy During his mandate, Alessandro Chiesi oversaw the Group t
Insurance Investment Outsourcing Surpasses $5.5 Trillion as Private Markets and Global Expansion Reshape the Industry20.5.2026 09:00:00 CEST | Press release
IIOR Shows Record Outsourced Insurance AUM, Private Assets Near $1 Trillion, and Europe Emerging as a Global Growth Engine Clearwater Analytics (NYSE: CWAN) today released the 2026 Insurance Investment Outsourcing Report (IIOR), produced in partnership with DCS Financial Consulting. The report captures $5.5 trillion in third-party general account insurance assets under management across 96 asset managers, a 23% increase year-over-year and a 65% increase since 2021, alongside $1.8 trillion in assets under advisement across 12 investment consultants. The findings point to an outsourcing market that has become larger, more global, and materially more complex. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520780028/en/ The 2026 IIOR reveals defining trends reshaping insurance investment management: Private Markets Cross a Threshold. Third-party private insurance AUM has more than doubled since 2021, reaching $947 billion and
Factbird Adds Quality & Compliance and Reports to its Manufacturing Intelligence Platform20.5.2026 08:00:00 CEST | Press release
Two new capabilities give multi-site manufacturers standardized workflows, traceable records, and automated reporting across every plant. Today, Factbird is announcing two major additions to its manufacturing intelligence platform: Quality & Compliance and Factbird Reports. Both address a problem that compounds as manufacturers grow. More sites mean more variation in how work gets done. More regulation means more documentation pressure on frontline teams. And more data, when fragmented across systems, often slows decisions rather than speeding them up. Solving this has traditionally meant large IT projects and months of deployment. “Enterprise manufacturers shouldn’t have to choose between capability and simplicity,” said Mogens Arne Hansen, Chief Technology and Product Officerat Factbird. “With Quality & Compliance and Reports, you can have standardized, audit-ready operations and automated performance reporting across every site, deployed in days, used by the people on the floor.” Qu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom